Dr Curigliano is directly responsible for clinical studies and research programs concerning the Phase 0, I and early Phase II treatments in metastatic breast cancer and solid tumors for which experimental studies are active. He is the reference of many translational studies on breast cancer and the role of the immune system in the mechanisms of response to monoclonal antibodies and the tolerance mechanisms by which tumors escape the immune system.
Many translational projects focus on the identification of molecular determinants predictive of response or toxicity to new "target oriented" drugs for personalized medicine programs. His involvement is directed towards the creation, management, presentation and publication of scientific data obtained. In the last two years, he has been responsible for 31 phase I, II and III studies with innovative treatments in breast cancer and in some solid tumors. He is currently a member of the Steering Committee of four global studies related to breast cancer treatment (two in the adjuvant setting, one in the neoadjuvant setting, and one in metastatic disease; the latter is a global program of "molecular screening" in metastatic disease). He is member of the Independent Data Monitoring Committee of a major global study on adjuvant treatment of HER2 positive breast cancer. He graduated "cum laude" in Medicine at the Catholic University of the Sacred Heart in Rome in 1993. In 1997, he specialized "cum laude" in Medical Oncology. In 1993, he worked at the Department of Clinical Immunology of South Carolina Medical School, Hollings Cancer Center, Charleston, USA, dealing with immunophenotyping of solid tumors and applications of flow cytometry in the early diagnosis of cancer. From 1994 to 1995 Dr Curigliano worked at the Herbert Irving Comprehensive Cancer Center at Columbia University, New York, USA, working on molecular epidemiology (study projects on the carcinogenesis of bladder and lung tumors). In 2006 he completed his PhD in Medical Pathophysiology and Clinical Pharmacology at the University of Pisa, working on a project of pharmacogenomics in bladder tumors. From 1999 to 2006, he worked on Phase I and Phase II clinical research at the Unit of Clinical Pharmacology and New Drugs in the Department of Medicine of the European Institute of Oncology, directed by Dr. Filippo de Braud. From 2010 to 2013 he served as Co-Director of the Division of Medical Oncology, directed by Professor Aron Goldhirsch, managing the therapeutic approach of patients with solid tumors and coordinating the activities of the Department of Medical Oncology. In 2011, he was a visiting scientist and held seminars at Harvard Medical School, Dana Farber Cancer Center, where he taught on the Summer School course. His main field of interest is translational research and clinical development of new therapeutic approaches in the treatment of solid tumors, particularly in breast cancer.
He has been a member of the Scientific Advisory Council of the IBCSG (International Breast Cancer Study Group) since 2008 and from 2010 to 2013 he was a member of the Scientific Advisory Council of the BIG (Breast International Group). The IBCSG and BIG are cooperative groups conducting randomized multicenter studies on breast cancer. He is a principal investigator and co-investigator of numerous national and international research projects, funded by the Ministry of Health, the Italian Association for Cancer Research and the European Community. These projects focus on clinical immunology studies and the identification of predictors of response to treatments in breast cancer. He is an active member of the main national and international societies dealing with cancer research (AIOM, AACR, ESMO, ASCO). From December 2006 to December 2010, he was named "Expert Clinical Assessor for Oncology" at the European Medicines Agency, appointed by the Italian Drug Agency. He was the editor of the Project START (State of the Art Oncology in Europe). He is a member of the Breast Faculty of the European Society of Medical Oncology (ESMO), the European School of Oncology (ESO), and the faculty of the St Gallen Early Breast Cancer Conference. Dr Curigliano is the co-founder and scientific secretary of the International Cardio-Oncology Society (ICOS). He is a member of the editorial boards of the journals most cited in the world (Journal of Clinical Oncology) and Europe (Annals of Oncology) for clinical research in Medical Oncology. He is a reviewer for the most important journals of medical oncology at global level (in addition to the two journals for which he is part of the editorial committee, Nature Clinical Cancer Reviews, Journal of National Cancer Institute, Breast Cancer Research and Treatment, Nature Clinical Practice Oncology, Cancer Treatment Review, Breast Cancer Research, British Journal of Cancer, European Journal of Cancer, Breast Cancer Research, Critical Review in Hematology-Oncology). Since February 2013 he has been a member of the ESMO Press & Media Affairs Committee, one of the three leaders responsible for the scientific communication of the European Society of Medical Oncology. He is the author and coauthor of over 150 "peer reviewed" publications in international scientific journals, and of over 10 chapters in books. His cumulative personal Impact factor is 1.885, with H index of 23 (Personal Impact factor in 2013 was 113.3).